Compare conditions

Put any two — or three — conditions side by side, adult or pediatric, to spot the look-alike differences fast, row by row.

Hereditary Breast & Ovarian Cancer (BRCA)

—

In one line

·BRCA mutations disable critical DNA repair mechanisms, allowing cancer-causing genetic errors to accumulate unchecked in breast and ovarian tissues.

—

Normal physiology

·The BRCA1 and BRCA2 genes produce proteins that repair double-strand breaks in DNA, the most dangerous type of DNA damage. These proteins work as part of a larger repair system called homologous recombination (using a matching DNA template to fix breaks accurately). Every time a cell divides or encounters damaging agents like radiation or chemicals, BRCA proteins scan for broken DNA strands and coordinate precise repairs. This surveillance and repair process prevents mutations from becoming permanent in the cell's genetic code.

—

What goes wrong

·People with BRCA mutations inherit one broken copy of the repair gene from a parent, so every cell in their body starts with only one working copy. Over time, if that second working copy gets damaged in breast or ovarian tissue, the cell loses all DNA-repair ability. Without working BRCA genes, double-strand DNA breaks get repaired sloppily using backup methods that introduce mistakes, and these mistakes accumulate until the cell becomes cancerous.

—

Hallmark signs

—

Red flags · escalate now

·Family history of breast cancer before age 50 or ovarian cancer at any age (suggests hereditary mutation requiring genetic counseling)
·Male relative with breast cancer or personal/family history of pancreatic cancer (strongly suggests BRCA2 mutation)
·New breast mass, persistent nipple discharge, or palpable axillary lymph nodes (requires urgent imaging within 2 weeks)
·Abdominal bloating, pelvic pain, early satiety, or increased abdominal size in BRCA carrier (ovarian cancer symptoms requiring urgent ultrasound and CA-125)

—

Workup

·Genetic counseling session before testing
·Multi-gene panel blood test or targeted BRCA1/BRCA2 sequencing
·Variant classification review
·Annual breast MRI (magnetic resonance imaging) starting age 25-30
·Annual mammogram starting age 30 (alternating with MRI every 6 months)
·Transvaginal ultrasound and CA-125 blood test every 6 months (limited effectiveness)
·Colonoscopy screening per guidelines
·Genetic testing of tumor tissue (if cancer develops)

—

Treatment

·Risk-reducing bilateral mastectomy (removing both breasts)
·Risk-reducing bilateral salpingo-oophorectomy (removing fallopian tubes and ovaries) after childbearing complete, age 35-40
·Chemoprevention with tamoxifen (20 milligrams daily for 5 years) in premenopausal women
·Enhanced surveillance without risk-reducing surgery (patient choice)
·Genetic counseling for family members
·Cascade testing (testing relatives after positive result in family)

—

NCLEX trap

·BRCA carriers need alternating breast MRI and mammography every 6 months starting age 25-30 because mammography misses 30-40% of cancers in dense breast tissue common in young women.
·Salpingo-oophorectomy should occur by age 35-40 after childbearing is complete because ovarian cancer surveillance is ineffective and ovarian cancer mortality is high; short-term HRT can be used until natural menopause age.
·BRCA mutations confer high risk but not certainty; 45-70% develop breast cancer and 11-40% develop ovarian cancer by age 70, meaning 30-55% never develop breast cancer despite carrying the mutation.
·Men with BRCA mutations face increased prostate (up to 20%), pancreatic (3-5%), and male breast cancer (1-10% lifetime) risks, can pass mutations to children, and need screening starting at age 40 for prostate cancer.
·Pre-test genetic counseling is essential to discuss implications for family members, psychological impact, insurance discrimination protections under GINA, interpretation of variants of uncertain significance (VUS), and cascade testing.
·A negative test in an unaffected family member is uninformative until an affected relative tests positive; testing should start with the person who has cancer to identify the family mutation first.

—

Install Maldek by Hill as an app — studies work even offline